New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Oxytocin

Pancragen vs Oxytocin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Cognitive EnhancementSexual Health & Libido
Oxytocin
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
Half-Life
Short (minutes); sustained gene-regulatory effects
~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
Admin Route
SubQ, Oral
Intranasal, SubQ, IV
Research
Typical Dose
10 mg per day
20–40 IU
Frequency
Daily for 10–30 days
As needed (not daily long-term)
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Enhances social bonding and trust
  • Reduces social anxiety and fear of rejection
  • Improves autism spectrum symptoms (social cognition)
  • Reduces cortisol and stress reactivity
  • Enhances sexual arousal and intimacy
  • Promotes maternal behavior and bonding
  • May improve depressive symptoms
  • Appetite suppression and metabolic effects
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Mild uterine cramping (avoid in pregnancy)
  • Nasal irritation (intranasal)
  • Headache
  • Potential emotional over-attachment or jealousy amplification
  • +2 more
Stacks With